118 related articles for article (PubMed ID: 11295109)
1. High expression of the proliferation and apoptosis associated CSE1L/CAS gene in hepatitis and liver neoplasms: correlation with tumor progression.
Wellmann A; Flemming P; Behrens P; Wuppermann K; Lang H; Oldhafer K; Pastan I; Brinkmann U
Int J Mol Med; 2001 May; 7(5):489-94. PubMed ID: 11295109
[TBL] [Abstract][Full Text] [Related]
2. Implication of the proliferation and apoptosis associated CSE1L/CAS gene for breast cancer development.
Behrens P; Brinkmann U; Fogt F; Wernert N; Wellmann A
Anticancer Res; 2001; 21(4A):2413-7. PubMed ID: 11724300
[TBL] [Abstract][Full Text] [Related]
3. Tissue-specific alternative splicing of the CSE1L/CAS (cellular apoptosis susceptibility) gene.
Brinkmann U; Brinkmann E; Bera TK; Wellmann A; Pastan I
Genomics; 1999 May; 58(1):41-9. PubMed ID: 10331944
[TBL] [Abstract][Full Text] [Related]
4. [Expression of CAS in hepatocellular carcinoma tissues and its relationship with HBV infection].
Zang H; Zhao JM; Ji D; Sun YL; Zhou GD; Zhao YL; Chen GF
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2012 Aug; 26(4):285-7. PubMed ID: 23189846
[TBL] [Abstract][Full Text] [Related]
5. CSE1L/CAS: its role in proliferation and apoptosis.
Behrens P; Brinkmann U; Wellmann A
Apoptosis; 2003 Jan; 8(1):39-44. PubMed ID: 12510150
[TBL] [Abstract][Full Text] [Related]
6. Cellular apoptosis susceptibility protein and proliferation in human hepatocellular carcinoma.
Shiraki K; Fujikawa K; Sugimoto K; Ito T; Yamanaka T; Suzuki M; Yoneda K; Sugimoto K; Takase K; Nakano T
Int J Mol Med; 2006 Jul; 18(1):77-81. PubMed ID: 16786158
[TBL] [Abstract][Full Text] [Related]
7. u-PA and c-MET mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma.
Tavian D; De Petro G; Benetti A; Portolani N; Giulini SM; Barlati S
Int J Cancer; 2000 Sep; 87(5):644-9. PubMed ID: 10925356
[TBL] [Abstract][Full Text] [Related]
8. The cellular apoptosis susceptibility CAS/CSE1L gene protects ovarian cancer cells from death by suppressing RASSF1C.
Lorenzato A; Martino C; Dani N; Oligschläger Y; Ferrero AM; Biglia N; Calogero R; Olivero M; Di Renzo MF
FASEB J; 2012 Jun; 26(6):2446-56. PubMed ID: 22389439
[TBL] [Abstract][Full Text] [Related]
9. Proliferating EpCAM-Positive Ductal Cells in the Inflamed Liver Give Rise to Hepatocellular Carcinoma.
Matsumoto T; Takai A; Eso Y; Kinoshita K; Manabe T; Seno H; Chiba T; Marusawa H
Cancer Res; 2017 Nov; 77(22):6131-6143. PubMed ID: 28951464
[TBL] [Abstract][Full Text] [Related]
10. Quantitative analysis of apoptosis-related gene expression in hepatocellular carcinoma.
Ikeguchi M; Hirooka Y; Kaibara N
Cancer; 2002 Nov; 95(9):1938-45. PubMed ID: 12404288
[TBL] [Abstract][Full Text] [Related]
11. Induction of lipocalin-2 expression in acute and chronic experimental liver injury moderated by pro-inflammatory cytokines interleukin-1β through nuclear factor-κB activation.
Borkham-Kamphorst E; Drews F; Weiskirchen R
Liver Int; 2011 May; 31(5):656-65. PubMed ID: 21457438
[TBL] [Abstract][Full Text] [Related]
12. Localization of the cell proliferation and apoptosis-associated CAS protein in lymphoid neoplasms.
Wellmann A; Krenacs L; Fest T; Scherf U; Pastan I; Raffeld M; Brinkmann U
Am J Pathol; 1997 Jan; 150(1):25-30. PubMed ID: 9006318
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic and pathogenetic implications of the expression of hepatic transporters in focal lesions occurring in normal liver.
Vander Borght S; Libbrecht L; Blokzijl H; Faber KN; Moshage H; Aerts R; Van Steenbergen W; Jansen PL; Desmet VJ; Roskams TA
J Pathol; 2005 Dec; 207(4):471-82. PubMed ID: 16161006
[TBL] [Abstract][Full Text] [Related]
14. [Hepatic neoductules].
Fischer HP; Meybehm M; Zhou H; Schoch J
Verh Dtsch Ges Pathol; 1995; 79():36-46. PubMed ID: 8600693
[TBL] [Abstract][Full Text] [Related]
15. Claudin-7 protein differentiates canine cholangiocarcinoma from hepatocellular carcinoma.
Jakab C; Kiss A; Schaff Z; Szabó Z; Rusvai M; Gálfi P; Szabára A; Sterczer A; Kulka J
Histol Histopathol; 2010 Jul; 25(7):857-64. PubMed ID: 20503174
[TBL] [Abstract][Full Text] [Related]
16. Enhanced expression of the protein kinase substrate annexin in human hepatocellular carcinoma.
Masaki T; Tokuda M; Ohnishi M; Watanabe S; Fujimura T; Miyamoto K; Itano T; Matsui H; Arima K; Shirai M; Maeba T; Sogawa K; Konishi R; Taniguchi K; Hatanaka Y; Hatase O; Nishioka M
Hepatology; 1996 Jul; 24(1):72-81. PubMed ID: 8707286
[TBL] [Abstract][Full Text] [Related]
17. Expression of c-myc mRNA in hepatocellular carcinomas, noncancerous livers, and normal livers.
Ikeguchi M; Hirooka Y
Pathobiology; 2004; 71(5):281-6. PubMed ID: 15459488
[TBL] [Abstract][Full Text] [Related]
18. SND1 affects proliferation of hepatocellular carcinoma cell line SMMC-7721 by regulating IGFBP3 expression.
Yin J; Ding J; Huang L; Tian X; Shi X; Zhi L; Song J; Zhang Y; Gao X; Yao Z; Jing X; Yang J
Anat Rec (Hoboken); 2013 Oct; 296(10):1568-75. PubMed ID: 23878061
[TBL] [Abstract][Full Text] [Related]
19. Prosurvival function of the cellular apoptosis susceptibility/importin-α1 transport cycle is repressed by p53 in liver cancer.
Winkler J; Ori A; Holzer K; Sticht C; Dauch D; Eiteneuer EM; Pinna F; Geffers R; Ehemann V; Andres-Pons A; Breuhahn K; Longerich T; Bermejo JL; Gretz N; Zender L; Schirmacher P; Beck M; Singer S
Hepatology; 2014 Sep; 60(3):884-95. PubMed ID: 24799195
[TBL] [Abstract][Full Text] [Related]
20. CAS (CSE1L) signaling pathway in tumor progression and its potential as a biomarker and target for targeted therapy.
Jiang MC
Tumour Biol; 2016 Oct; 37(10):13077-13090. PubMed ID: 27596143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
